The Chief Executive Officer and President of Fate Therapeutics is Dr. Bahram (Bob) Valamehr, who guides the company's overarching corporate strategy, financial administration, and research and development initiatives. Having spent over a decade leading Fate's iPSC platform development and serving previously as President of Research and Development, he brings extensive scientific expertise in stem cell biology, immunology, and oncology. Under his executive leadership, the organization continues to advance its clinical pipeline of programmed cellular immunotherapies designed to treat cancer and autoimmune diseases.